TY  - JOUR
AU  - Körber, Stefan
AU  - Röhrich, Manuel
AU  - Walkenbach, Leon
AU  - Liermann, Jakob
AU  - Choyke, Peter L
AU  - Fink, Christoph
AU  - Schroeter, Cathrin
AU  - Spektor, Anna-Maria
AU  - Herfarth, Klaus
AU  - Walle, Thomas
AU  - Calais, Jeremie
AU  - Kauczor, Hans-Ulrich
AU  - Jaeger, Dirk
AU  - Debus, Jürgen
AU  - Haberkorn, Uwe
AU  - Giesel, Frederik L
TI  - Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
JO  - Journal of nuclear medicine
VL  - 64
IS  - 11
SN  - 0097-9058
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2023-01829
SP  - 1712-1720
PY  - 2023
N1  - #EA:E050# / 2023 Nov;64(11):1712-1720
AB  - Since the development of fibroblast activation protein-targeted radiopharmaceuticals, 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for detecting primary and metastatic lesions in many types of tumors. However, there is currently a lack of reliable data regarding the clinical impact of this family of probes. To address this gap, the present study aimed to analyze the clinical impact of 68Ga-FAPI PET/CT by examining a large cohort of patients with various tumors. Methods: In total, 226 patients (137 male and 89 female) were included in this retrospective analysis. Pancreatic cancer and head and neck cancers were the most common tumor types in this cohort. TNM stage and oncologic management were initially determined with gold standard imaging, and these results were compared with 68Ga-FAPI PET/CT. Changes were classified as major and minor. Results: For 42
KW  - FAPI (Other)
KW  - PET/CT (Other)
KW  - management (Other)
KW  - radiation therapy (Other)
KW  - staging (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:37678928
DO  - DOI:10.2967/jnumed.123.266046
UR  - https://inrepo02.dkfz.de/record/282683
ER  -